Sun K706 is a novel tyrosine kinase inhibitor, intended for the treatment of chronic myelogenous leukemia (CML). While currently available oral drugs like Imatinib (Gleevec®), Nilotinib (Tasigna®) and Dasatinib (Spycel®) are quite effective chemotherapeutic agents for CML, these drugs are ineffective on the most resistant form of mutation in leukemic cells, viz. the T315I mutation. In fact, currently there is no approved drug for the patients who become resistant to therapy and are diagnosed with the T315I mutation. Besides, the current therapeutic agents are also known to cause cardiac side effects (QT prolongation), myelosupression, liver toxicity, bleeding, electrolyte imbalance and fluid retention.
Our novel NCE SUN-K706 targets this T315I resistance in CML. In vitro studies have demonstrated that SUN-K706 potently inhibits, besides other major mutant forms, the T315I mutant of the Abl kinase. Further, preclinical studies to demonstrate safety and efficacy are underway. Toxicity studies that are required for filing IND application are expected to be completed and subsequently IND would be filed.
For updates,please see the latest investor update presentation and transcript.